2023 World Conference on Lung Cancer (Posters)-EP07.01. Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable

EP07.01. Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable - PDF(Slides)

Back to course

Pdf Summary

This research article discusses the use of stereotactic body radiation therapy (SBRT) as an alternative treatment for early-stage non-small cell lung cancer (NSCLC) in patients who cannot undergo surgery. The study aims to evaluate the outcomes of SBRT in patients with inoperable peripheral tumors.<br /><br />The study protocol includes clinical examination, imaging tests, tumor biopsy, and multidisciplinary tumor board consultation. The patients are followed up and evaluated for progression-free survival, objective response rate, overall survival, and toxicity.<br /><br />The study found that SBRT had promising results, with a median progression-free survival of 29.23 months and 2-year and 3-year progression-free survival rates of 59.8% and 42.3% respectively. The overall survival rate ranged from 96.8% at 1 year to 42.1% at 5 years. The SUVmax value before treatment was found to be related to both progression-free survival and overall survival. Disease control at 3 months after SBRT also correlated with improved local control rate and progression-free survival.<br /><br />The adverse effects of SBRT were evaluated, with grade 3 adverse events occurring in 7 patients and grade 4 adverse events in 2 patients. However, none of the patients died as a result of SBRT. Spirometry parameters did not show significant changes before and after SBRT.<br /><br />In conclusion, SBRT is an effective radical treatment option for early-stage NSCLC in patients who are ineligible for surgery. The SUVmax value before treatment and disease control rate at 3 months are predictive of patient survival. SBRT is considered a safe method of treatment.<br /><br />This research article provides valuable insights into the use of SBRT as an alternative treatment for early-stage NSCLC. The findings can potentially contribute to improving the management and outcomes of patients who are ineligible for surgery.

Asset Subtitle

Luan Pham

Meta Tag

Speaker Luan Pham

Topic Early-Stage NSCLC: Best Practice

Keywords

stereotactic body radiation therapy

SBRT

alternative treatment

early-stage non-small cell lung cancer

NSCLC

inoperable peripheral tumors

progression-free survival

objective response rate

overall survival

toxicity